Silver Book Fact

Potential cost effectiveness of shingles vaccines

The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal perspective.

Pellesier J, Brisson M, Levin M. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier J, Brisson M, Levin M
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Reduction in hospital-acquired HAIs could produce significant savings
    Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
  • Measles vaccines reduced cases from 6 million to 1 million per year
    Vaccination for measles reduced the number of worldwide deaths from 6 million in 1974 to less than 1 million per year.  
  • Potential value of pneumonia vaccine
    Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
  • Diptheria vaccine significantly reduced annual cases
    Vaccination has played a significant role in reducing diphtheria cases from 80,000 in 1975 to less than 10,000 per year.  
  • Immunization significantly lowers rates of leading infectious diseases
    Impact of Immunization on the Number of Annual Cases of Disease in the USA